NEW YORK (GenomeWeb News) – The University of Maryland Biotechnology Institute said Monday that it has spun out a proteomics venture that will commercialize protein characterization and quantification technology.
The new Rockville-based company, called Omic Biosystems, will market a technology called DiART (deuterium (2H) isobaric amine reactive tags) that uses protein tagging designs coupled with sample preparation technology for use in large-scale mass spectrometry proteomics studies.
Omic Biosystems CEO and Co-founder Feng Tao said in a statement that the company will "help solve important bottleneck problems in the field of proteomics."
"The immediate market impact of this technology is its utility in biomarker discoveries," UMBI's Director of Technology Transfer and Commercialization, Jonathan Gottlieb, said in a statement. "Its broader impact will facilitate the translation of genomic and proteomic information into relevant clinical information that can be applied to new drug discovery and clinical diagnostics."
The DiART technology was developed at UMBI's Center for Advanced Research in Biotechnology in the lab of UMBI Assistant Professor and Omic Biosystems' Co-founder Shuwei Li.